email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
406 - 420
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Unicar-Therapy Publishes Positive Data for Dual-Target CAR T-cell Leukemia Therapy
$5.00
Available
ProfoundBio Provides Updates on Two ADC Candidates in US-China Trials
$5.00
Available
Ascentage Details ASCO Abstracts for Four Novel Cancer Drugs
$5.00
Available
Lynk Doses First Cohort of Psoriasis Patients with Topical Third-Gen JAK Inhibitor
$5.00
Available
Accropeutics to Start Phase I Trial of TYK2/JAK1 Inhibitor for Psoriasis
$5.00
Available
Allgenesis Reports Positive Data from US Trial of Diabetic Macular Edema Therapy
$5.00
Available
BioRay to Start Trials of LIV-1 Targeting ADC for Advanced Malignant Tumors
$5.00
Available
Antengene Awarded Orphan Status for Claudin 18.2 ADC in Two Cancer Indications
$5.00
Available
Minghui Pharma Doses First Subject in Phase I Trial of Autoimmune Candidate
$5.00
Available
Laekna to Start Phase I/II Trials of ATP Inhibitor in US for Lung Cancer
$5.00
Available
HanxBio Approved to Start US Trials of anti-CD47/PD-1 for Lymphoma
$5.00
Available
CARsgen Starts US Phase II Trial of CLDN18.2 CAR-T for Gastric Cancer
$5.00
Available
Boan Bio Approved to Start Trials of Bispecific Antibody for CEA Solid Tumor Cancers
$5.00
Available
Hengrui Affiliate Files for US Approval of PD-1 in Early Liver Cancer
$5.00
Available
CANbridge Reports Data From Preclinical Test of Gene Therapy for Spinal Muscular Atrophy
$5.00
Available